Ads
related to: novartis patient assistance application form print version 10SCBN.org has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Capmatinib. Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR. [2] [3] [4] [5]
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Nilotinib. Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [4] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.
The drug, soticlestat, was being tested in combination with standard-of-care treatment in adults and children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) - rare and severe forms of ...
Lapatinib. Lapatinib ( INN ), used in the form of lapatinib ditosylate ( USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours. [2] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. [3]
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory ...
Sacubitril/valsartan, sold under the brand name Entresto, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). [9]
Novartis fought a protracted battle with the government of India over the patenting of its drug, Gleevec, in India, which ended up in a Supreme Court in a case known as Novartis v. Union of India & Others. The Supreme Court ruled narrowly against Novartis, but opponents of patenting drugs claimed it as a major victory. Environmental issues
Ads
related to: novartis patient assistance application form print version 10SCBN.org has been visited by 10K+ users in the past month